Intracellular Accumulations: Lipids, Proteins, Glycogen, Pigments, Causes and Diagnosis

Learning outcomes

• Define intracellular accumulation and list the four major mechanisms by which it develops.
• Classify accumulations into lipids, proteins, glycogen, pigments and selected minerals.
• Explain fatty change, cholesterol accumulation, protein droplets, glycogen storage and major endogenous/exogenous pigments.
• Recognise important histologic stains and their limitations.
• Distinguish benign adaptive storage from inherited storage disease, toxic injury and premalignant change.
• Interpret organ-specific examples in liver, kidney, heart, macrophages, lung, skin and nervous system.
• Apply the concepts to clinical presentations and emergency complications such as acute liver failure, metabolic decompensation and haemolysis.

1. Definition and the four mechanisms

Accumulation reflects an imbalance between production or uptake and the cell’s ability to use, package, degrade or export a substance. Robbins-style classification recognises four broad mechanisms:

Mechanism	What fails?	Examples
Abnormal metabolism or uptake	A normal substance is produced or delivered in excess of normal processing capacity.	Triglyceride accumulation in fatty liver; cholesterol in atherosclerotic macrophages.
Defective folding, transport or export	A normal or abnormal protein cannot fold, move through the ER/Golgi or leave the cell.	Alpha-1-antitrypsin in hepatocyte ER; immunoglobulin in plasma cells.
Inherited enzyme deficiency	A metabolite cannot be degraded and accumulates in lysosomes or cytoplasm.	Gaucher, Tay-Sachs, Pompe and other lysosomal storage diseases.
Inability to degrade ingested material	Phagocytes internalise substances that resist digestion.	Carbon pigment, silica, tattoo ink and some microorganisms.

2. Lipid accumulations

2.1 Triglyceride accumulation (steatosis)

Steatosis is abnormal storage of triglycerides within parenchymal cells, especially hepatocytes. The liver receives fatty acids from diet and adipose tissue, synthesises fatty acids, oxidises them and packages them into VLDL. Steatosis develops when delivery or synthesis exceeds oxidation and export.

Mechanisms in the liver

• Increased free-fatty-acid delivery from adipose tissue during starvation, obesity, insulin resistance or catecholamine excess.
• Increased de novo lipogenesis, often related to insulin resistance and metabolic syndrome.
• Reduced fatty-acid oxidation from hypoxia, mitochondrial injury or toxins.
• Impaired apoprotein synthesis or VLDL assembly, as with protein malnutrition or some toxins.
• Blocked lipoprotein secretion from hepatocytes.

Causes

Cause	Mechanism/clinical context
Alcohol	NADH excess from ethanol metabolism inhibits fatty-acid oxidation and promotes triglyceride synthesis; acetaldehyde and oxidative stress add injury.
Obesity and type 2 diabetes	Insulin resistance increases free-fatty-acid flux and de novo lipogenesis.
Starvation and severe malnutrition	Adipose mobilisation increases hepatic fatty-acid delivery; protein deficiency limits VLDL export.
Hypoxia/ischaemia	Mitochondrial oxidation falls.
Toxins and drugs	Carbon tetrachloride, tetracycline, valproate, corticosteroids and some antiretrovirals can impair oxidation or export.
Pregnancy and metabolic disease	Acute fatty liver of pregnancy and metabolic disorders can produce rapid hepatocellular dysfunction.

Morphology

• Microvesicular steatosis: many small lipid vacuoles, central nucleus; seen in acute fatty liver, Reye syndrome, valproate toxicity and mitochondrial disorders.
• Macrovesicular steatosis: one or a few large clear vacuoles displace the nucleus to the cell periphery; common in alcohol-associated and metabolic fatty liver.
• Gross liver: enlarged, yellow, soft and greasy in substantial steatosis.
• Stain: routine processing dissolves lipid, leaving clear vacuoles. Oil Red O or Sudan stains demonstrate neutral lipid in frozen sections.

Clinical progression

Steatosis may be asymptomatic or cause hepatomegaly and mild transaminase elevation. Persistent metabolic injury can progress to steatohepatitis, hepatocyte ballooning, Mallory-Denk bodies, inflammation, fibrosis, cirrhosis and hepatocellular carcinoma. Alcohol-associated disease adds acetaldehyde toxicity and gut-derived inflammatory signalling.

2.2 Cholesterol and cholesteryl ester accumulation

Cells accumulate cholesterol when uptake is excessive, synthesis is increased or efflux is impaired.

• Atherosclerosis: macrophages take up oxidised LDL through scavenger receptors and become foam cells; smooth-muscle cells also accumulate lipid. Cholesterol crystals and necrotic debris form the atheromatous core.
• Xanthomas: dermal macrophages filled with lipid produce yellow plaques or nodules in hyperlipidaemia.
• Cholesterolosis: macrophages accumulate cholesterol in the gallbladder wall, producing a “strawberry gallbladder.”
• Niemann-Pick disease: sphingomyelin or cholesterol-related lysosomal storage causes foam cells, organomegaly and neurologic disease in some subtypes.

2.3 Phospholipid accumulation

Some drugs (for example, amiodarone and certain cationic amphiphilic agents) inhibit lysosomal phospholipases and cause phospholipid-rich lamellar bodies. The process may produce phospholipidosis in lung, liver, kidney or eye. It often improves after the drug is withdrawn, but organ dysfunction can occur.

3. Protein accumulations

3.1 Reabsorption droplets in renal tubules

Proteinuria causes proximal tubular cells to endocytose filtered albumin and immunoglobulin. The proteins accumulate in eosinophilic cytoplasmic droplets. Treating the glomerular leak reduces the load; persistent heavy proteinuria causes tubular injury and interstitial fibrosis.

3.2 Alpha-1-antitrypsin deficiency

Mutant alpha-1-antitrypsin (especially the Z variant) misfolds and polymerises in hepatocyte ER, forming periodic acid–Schiff (PAS)-positive, diastase-resistant globules. Loss of circulating inhibitor predisposes to emphysema, while hepatic accumulation causes hepatitis, cirrhosis and hepatocellular carcinoma.

3.3 Immunoglobulin and Russell bodies

Plasma cells synthesising large amounts of immunoglobulin may accumulate eosinophilic globules called Russell bodies. Numerous bodies produce Mott cells. They occur in chronic inflammation and plasma-cell neoplasms and are not by themselves diagnostic of malignancy.

3.4 Mallory-Denk bodies

These are cytoplasmic aggregates of damaged intermediate filaments (keratins 8 and 18) in hepatocytes. They are seen in alcohol-associated hepatitis, metabolic steatohepatitis and some cholestatic or Wilson-related diseases. They indicate cellular stress but are not specific for alcohol.

3.5 Amyloid

Amyloid is extracellular rather than truly intracellular, but it is often taught with abnormal protein accumulations. Misfolded fibrils deposit in tissue, bind Congo red and show apple-green birefringence under polarised light. The distinction matters: intracellular ER globules and extracellular amyloid require different diagnostic approaches.

4. Glycogen accumulations

4.1 Mechanism

Glycogen accumulates when glucose metabolism is abnormal, insulin signalling is excessive or a lysosomal/cytosolic enzyme is deficient. It appears as clear cytoplasmic vacuoles on H&E and stains magenta with PAS. Diastase digestion removes glycogen, helping distinguish it from other PAS-positive material.

4.2 Diabetes mellitus

Hyperglycaemia and abnormal insulin signalling can cause glycogen accumulation in renal tubular epithelium, hepatocytes, pancreatic beta cells and cardiac muscle. In kidney, glycogen-rich tubular cells may contribute to Armanni–Ebstein changes in severe diabetes. The central disease problem remains hyperglycaemia, vascular injury and metabolic decompensation.

4.3 Glycogen storage diseases

Disease	Defect/example	Main clinical pattern
von Gierke (type I)	Glucose-6-phosphatase deficiency.	Severe fasting hypoglycaemia, lactic acidosis, hyperuricaemia and hepatomegaly.
Pompe (type II)	Lysosomal acid alpha-glucosidase deficiency.	Cardiomyopathy, hypotonia and respiratory weakness.
Cori (type III)	Debranching-enzyme deficiency.	Hepatomegaly, hypoglycaemia and skeletal/cardiac muscle involvement.
McArdle (type V)	Muscle glycogen phosphorylase deficiency.	Exercise intolerance, cramps, myoglobinuria and rhabdomyolysis.
Hers (type VI)	Liver glycogen phosphorylase deficiency.	Milder fasting hypoglycaemia and hepatomegaly.

Emergency clues include unexplained hypoglycaemia, lactic acidosis, cardiomyopathy, recurrent rhabdomyolysis or fasting intolerance. Stabilise glucose, assess acid-base/electrolytes and involve metabolic specialists; definitive management depends on the enzyme defect.

5. Pigment accumulations

Pigments are coloured substances that may be exogenous or endogenous. The microscopic colour and chemical stain help identify them.

5.1 Exogenous pigments

Pigment	Source and site	Appearance/clinical significance
Carbon (anthracosis)	Inhaled air pollution or smoke; alveolar macrophages and hilar lymph nodes.	Black granular pigment; usually harmless, but heavy exposure may accompany pneumoconiosis.
Silica and asbestos	Occupational inhalation; macrophages and lung interstitium.	Trigger fibrosis, restrictive disease and malignancy risk.
Tattoo pigment	Injected dermis; macrophages and regional lymph nodes.	Persistent coloured granules; may rarely cause allergy or granulomatous inflammation.
Therapeutic/foreign material	Injected fillers, talc or environmental particles.	Foreign-body reactions, embolic disease or local inflammation.

5.2 Lipofuscin

Lipofuscin is a yellow-brown, finely granular “wear-and-tear” pigment produced by lipid peroxidation and incomplete lysosomal digestion. It accumulates in long-lived cells such as cardiac myocytes, hepatocytes and neurons with ageing or chronic atrophy (“brown atrophy” of the heart). It is usually a marker of previous oxidative injury rather than a direct cause of cell death.

5.3 Melanin

Melanin is produced by melanocytes from tyrosine and transferred to keratinocytes. Increased melanin occurs in sun exposure, post-inflammatory hyperpigmentation, Addison disease and some melanocytic lesions. It is brown-black and can be demonstrated with Fontana–Masson stain. Melanin must be distinguished from hemosiderin and exogenous carbon.

5.4 Hemosiderin and iron

Hemosiderin is an iron-storage pigment formed from ferritin aggregates. Macrophages accumulate it after haemorrhage; iron overload produces widespread storage in liver, pancreas, heart and endocrine organs.

• Local haemosiderosis: bruising, pulmonary congestion or repeated haemorrhage; macrophages contain coarse golden-brown granules.
• Systemic haemosiderosis: transfusions, chronic haemolysis or excessive iron absorption.
• Haemochromatosis: iron-mediated injury causes cirrhosis, diabetes, cardiomyopathy, hypogonadism and skin bronzing.
• Stain: Prussian blue (Perls) highlights ferric iron.

5.5 Bilirubin and bile pigments

Hepatocytes and canaliculi can accumulate yellow-green bile pigment during cholestasis or severe haemolysis. Bilirubin deposition may injure neurons in neonatal kernicterus. Clinically, jaundice, dark urine, pale stools, pruritus and rising bilirubin prompt evaluation of haemolysis, hepatocellular disease or obstruction.

5.6 Copper

Copper accumulates in Wilson disease, particularly in liver, brain, cornea and kidneys. It promotes oxidative injury and may cause hepatitis, cirrhosis, neuropsychiatric symptoms and Kayser–Fleischer rings. Rhodanine or orcein stains can demonstrate copper-associated protein, but serum ceruloplasmin, urinary copper and specialist testing are required for diagnosis.

6. Selected inherited storage diseases

Disorder	Stored material/compartment	Key clinical features
Gaucher disease	Glucocerebroside in lysosomes of macrophages.	Hepatosplenomegaly, cytopenias, bone pain and “crumpled tissue paper” macrophages.
Niemann-Pick disease	Sphingomyelin or cholesterol-related storage.	Hepatosplenomegaly, foam cells, neurodegeneration in severe forms.
Tay-Sachs disease	GM2 ganglioside in neurons and macrophages.	Progressive neurodegeneration and cherry-red macula.
Fabry disease	Globotriaosylceramide in vascular/endothelial and other cells.	Neuropathic pain, angiokeratomas, renal and cardiac disease.
Pompe disease	Glycogen in lysosomes, especially cardiac and skeletal muscle.	Infantile cardiomyopathy or late-onset limb-girdle/respiratory weakness.
Alpha-mannosidosis	Oligosaccharides in lysosomes.	Immunodeficiency, skeletal abnormalities and cognitive impairment.

These disorders are diagnosed by enzyme assay, genetic testing, substrate measurement and organ-specific evaluation. Some have enzyme-replacement, substrate-reduction or chaperone therapies; early diagnosis changes prognosis.

7. Why accumulations injure cells

• Organelle crowding: storage distorts ER, lysosomes, mitochondria and cytoskeleton.
• Membrane damage: free fatty acids, cholesterol crystals and iron-catalysed ROS injure lipid bilayers.
• ER stress: misfolded proteins activate the unfolded-protein response and apoptosis.
• Inflammation: cholesterol crystals and damaged lysosomes activate inflammasomes.
• Mechanical obstruction: pigment or protein plugs can block ducts or tubular lumens.
• Functional replacement: storage can enlarge but weaken an organ, as in cardiomyopathy or hepatomegaly.
• Genomic instability: chronic oxidative injury may increase dysplasia and cancer risk.

8. Diagnostic approach

8.1 Clinical questions

1. Is the accumulation localised or systemic?
2. Is the patient exposed to alcohol, drugs, occupational dust, transfusions or toxins?
3. Are there signs of metabolic disease, malnutrition, diabetes, haemolysis or inherited disease?
4. Which organs are enlarged or failing?
5. Is the process reversible after removing the cause?

8.2 Histochemical stains

Stain/test	Material highlighted	Key caution
Oil Red O/Sudan	Neutral lipid in fresh/frozen tissue.	Routine paraffin processing removes most lipid.
PAS	Glycogen, mucin, basement membrane and some fungal walls.	Diastase digestion helps confirm glycogen.
Prussian blue (Perls)	Ferric iron/hemosiderin.	Negative stain does not exclude all iron states.
Fontana–Masson	Melanin and some argentaffin materials.	Interpret with morphology and immunostains.
Congo red	Amyloid (extracellular).	Requires apple-green birefringence for supportive confirmation.
Rhodanine/orcein	Copper or copper-associated protein.	Biochemical testing is still required for Wilson disease.
Polarised light	Crystals, birefringent foreign material and some lipid.	Appearance is not specific without clinical context.

8.3 Laboratory and imaging assessment

• Liver: AST/ALT, bilirubin, INR, albumin, glucose, lipid profile, viral tests, ultrasound/elastography and biopsy when indicated.
• Iron: ferritin, transferrin saturation, full blood count and genetic testing; ferritin also rises with inflammation.
• Copper: ceruloplasmin, 24-hour urine copper, liver copper and slit-lamp examination.
• Storage disease: enzyme assays, genetic panels and specialist metabolic testing.
• Muscle: CK, electrolytes, urine myoglobin and cardiac evaluation for glycogen disorders.
• Imaging: MRI can quantify iron, fat and organ volume; ultrasound and CT show hepatosplenomegaly, steatosis or calcification.

9. Emergency presentations

9.1 Acute fatty liver and liver failure

Rapid microvesicular steatosis in pregnancy, toxin exposure or mitochondrial dysfunction can progress to hypoglycaemia, coagulopathy, encephalopathy, renal injury and lactic acidosis. Stabilise glucose, manage airway and cerebral risk, monitor INR/renal function and involve obstetric, hepatology and critical-care teams early.

9.2 Iron overload and cardiac injury

Iron deposition can cause restrictive or dilated cardiomyopathy and arrhythmias. Patients with syncope, heart failure, chest pain or palpitations require ECG, troponin, echocardiography and specialist assessment. Do not assume every high ferritin value represents iron overload; inflammation and liver disease also elevate ferritin.

9.3 Glycogen storage decompensation

Hypoglycaemia, lactic acidosis, hyperkalaemia, cardiomyopathy or rhabdomyolysis can be precipitated by fasting, infection or exertion. Give prompt glucose, avoid prolonged fasting, correct life-threatening electrolytes and seek metabolic guidance.

9.4 Toxic accumulation

Overdose, drug-induced phospholipidosis, paracetamol injury and carbon monoxide can produce rapid intracellular dysfunction. Obtain the exposure history, contact a poison centre, use time-sensitive antidotes and monitor organ function even before routine enzymes rise.

10. Applied cases

Case 1: Metabolic fatty liver

An adult with central obesity, hypertension and type 2 diabetes has hepatomegaly and mild ALT elevation. Macrovesicular triglyceride accumulation reflects insulin resistance and altered fatty-acid flux. Assess metabolic risk, fibrosis risk, alcohol and medication history. Lifestyle and metabolic control can improve steatosis; established fibrosis requires specialist follow-up.

Case 2: Alpha-1-antitrypsin disease

A young adult has emphysema with minimal smoking exposure and a relative with cirrhosis. Misfolded Z alpha-1-antitrypsin accumulates in hepatocyte ER while the lung loses antiprotease protection. Test serum level and genotype/phenotype; assess lung and liver, avoid smoking and involve specialists.

Case 3: Rhabdomyolysis in McArdle disease

A patient develops severe muscle pain and cola-coloured urine after strenuous exertion. Defective muscle glycogen breakdown causes energy failure and muscle-cell membrane damage. Check CK, potassium, calcium, creatinine and ECG; treat rhabdomyolysis and investigate inherited metabolic disease after stabilisation.

11. Intracellular accumulation versus other pathology terms

Term	Meaning	Example
Accumulation	Material stored within a cell above normal levels.	Hemosiderin in macrophages.
Infiltration	Material or cells enter tissue, often from blood or adjacent structures.	Fatty infiltration of the liver or tumour infiltration.
Degeneration	Broad descriptive term for abnormal cellular structure/function, often reversible.	Hydropic degeneration or fatty change.
Storage disease	Inherited or acquired defect causing systemic substrate accumulation.	Gaucher disease.
Calcification	Calcium salt deposition; may be intracellular early but is usually discussed as tissue mineralisation.	Dystrophic calcification in dead tissue.

12. Management principles

1. Remove the source: stop alcohol or offending drugs, treat toxins and correct occupational exposure.
2. Correct the metabolic driver: manage diabetes, obesity, malnutrition, dyslipidaemia, hypoglycaemia and endocrine disease.
3. Use disease-specific therapy: enzyme replacement, chelation, substrate reduction, chaperones or transplantation when indicated.
4. Protect organs: monitor liver synthetic function, renal function, glucose, electrolytes, cardiac rhythm and neurological status.
5. Investigate family members: inherited storage disease has implications for relatives and future pregnancies.
6. Do not overinterpret one stain: correlate morphology, chemistry, genetics, imaging and clinical findings.

13. Quick self-test

1. Name the four major mechanisms of intracellular accumulation.
   Answer: Abnormal metabolism/uptake, defective folding/transport/export, inherited enzyme deficiency and inability to degrade ingested material.
2. Why does routine H&E show clear vacuoles in fatty liver?
   Answer: Organic solvents remove triglyceride during tissue processing.
3. Which stain demonstrates glycogen?
   Answer: PAS, with diastase sensitivity supporting glycogen.
4. Which stain demonstrates hemosiderin?
   Answer: Perls’ Prussian blue.
5. What pigment produces brown atrophy of the heart?
   Answer: Lipofuscin.
6. What is the key lung–liver link in alpha-1-antitrypsin deficiency?
   Answer: Misfolded protein accumulates in hepatocyte ER causing liver disease, while low circulating antiprotease predisposes to emphysema.
7. Which metabolic emergency may follow rapid tumour-cell apoptosis?
   Answer: Tumour lysis syndrome with hyperkalaemia, hyperphosphataemia, hypocalcaemia, hyperuricaemia and acute kidney injury.
8. Why is ferritin not a specific measure of iron overload?
   Answer: Ferritin is also an acute-phase reactant and rises with inflammation, infection and liver disease.

14. Take-home summary

Selected references

• NCBI Bookshelf: Cell Injury, Cell Death and Adaptations
• NCBI Bookshelf: Histology, Cell Death and Cellular Pathology
• NCBI Bookshelf: Nonalcoholic Fatty Liver Disease
• GeneReviews: Alpha-1 Antitrypsin Deficiency
• GeneReviews: Lysosomal Storage Diseases

Educational note: This resource supports learning and clinical reasoning. Current local protocols, senior supervision and national guidelines take precedence in patient care.